Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Biotech
Inhibrx’s OX40-Keytruda combo shows promise in early ph. 2 data
Adding Inhibrx’s OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance the program.
Nick Paul Taylor
May 11, 2026 10:06am
Werewolf weighs sale or merger as cash reserves whimper
Feb 24, 2026 5:23pm
AstraZeneca's ph. 3 cancer fail is latest blow to ATR inhibitors
Dec 22, 2025 4:35am
Arcus halts Gilead-partnered TIGIT trials as it reworks R&D
Dec 12, 2025 10:00am
Crescent inks $80M Kelun deal, adding ADC to mix with bispecific
Dec 4, 2025 9:50am
Ipsen inks €1B buyout of French biotech ImCheck
Oct 22, 2025 10:33am
